HER2-negative breast cancer: Adding dalpiciclib to fulvestrant prolongs PFS in phase 3December 18, 2021Breast Cancer
Long-term ovarian suppression with GnRHa safe in premenopausal early breast cancerDecember 18, 2021Breast Cancer
Chemoendocrine therapy beneficial in premenopausal women with node+ breast cancer and low recurrence scoreDecember 18, 2021Breast Cancer
Oncology PracticePostmenopausal women with early breast cancer can go chemo-freeDecember 17, 2021Breast Cancer
Oncology PracticeCardiovascular effects of breast cancer treatment vary based on weight, menopausal statusDecember 17, 2021Breast CancerMetastatic Breast Cancer
Oncology PracticeCancer risk tied to some manufactured foodsDecember 16, 2021Breast CancerMetastatic Breast CancerGenitourinary Cancer
Oncology PracticeBreast cancer-related musculoskeletal pain alleviated with acupunctureDecember 16, 2021Breast CancerMetastatic Breast Cancer
Oncology PracticeMore evidence ties some antipsychotics to increased breast cancer riskDecember 15, 2021Breast CancerGynecologic Cancer
Oncology PracticeSacituzumab govitecan effective in Black mTNBC patientsDecember 15, 2021Metastatic Breast CancerBreast Cancer
Oncology PracticePD-L1 cutoff for pembrolizumab in mTNBC confirmedDecember 15, 2021Metastatic Breast CancerBreast Cancer
Oncology PracticePembrolizumab improves event-free survival in early TNBCDecember 15, 2021Metastatic Breast CancerBreast Cancer
Oncology PracticeAntibiotic use associated with triple-negative breast cancer mortalityDecember 13, 2021Metastatic Breast CancerBreast Cancer
Oncology PracticeOmega-3 supplements may impact breast cancer riskDecember 13, 2021Metastatic Breast CancerBreast Cancer
Oncology PracticeWomen struggle with benzodiazepine addiction post chemotherapy treatmentDecember 13, 2021Metastatic Breast CancerBreast Cancer
Oncology Practice‘Surprising’ lack of benefit to adding palbociclib to endocrine therapy in early HR+/HER2– breast cancerDecember 13, 2021Metastatic Breast CancerBreast Cancer
